ACC pipeline
Response and survival, trial by trial.
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
8 arms have a reported figure in this set.
B7-H4-directed ADC 2
Emi-Le, ACC efficacy cohort
Phase 1 doses (not stated in source) · Single arm
R/M ACC, evaluable (n = 45)
disease control rate: 82.2%, ASCO 2026
median duration of response: 7.4 months, ASCO 2026
Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) · NCT05377996
Emi-Le, post hoc aggressive subtype
Phase 1 doses (not stated in source) · Single arm
ACC with solid histology or high-grade transformation (n = 32, post hoc)
median duration of response: 6.4 months, ASCO 2026; post hoc
Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) · NCT05377996
MYB mRNA degrader 2
REM-422 24 mg (RP2D), biomarker positive
24 mg · Single arm
R/M ACC, MYB biomarker positive at RP2D (n = 7)
disease control rate: 100%, ASCO 2026
ARIA · NCT06118086
REM-422 12 mg or more, biomarker positive
12 to 48 mg · Single arm
biomarker-positive R/M ACC (n = 30)
any target-lesion reduction: 70%, cutoff 01.07.2026
target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026
ARIA · NCT06118086
MYB splicing modulator 1
RGT-61159 at or below RP2D
at or below RP2D (mixed doses) · Single arm
R/R ACC, evaluable (n = 39)
disease control rate: 84.6%, ASCO 2026, preliminary
RGT-61159 Phase 1a/b · NCT06462183
VEGFR2 TKI 1
Rivoceranib 700 mg
700 mg · Single arm
R/M ACC (n = 80; 72 evaluable)
median duration of response (investigator): 14.9 months, primary analysis
Rivoceranib Phase 2 · NCT04119453
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.